Edition:
India

Pacira Biosciences Inc (PCRX.OQ)

PCRX.OQ on NASDAQ Stock Exchange Global Select Market

38.15USD
13 Sep 2019
Change (% chg)

$0.90 (+2.42%)
Prev Close
$37.25
Open
$37.40
Day's High
$38.27
Day's Low
$37.25
Volume
126,658
Avg. Vol
161,004
52-wk High
$54.92
52-wk Low
$34.64

Latest Key Developments (Source: Significant Developments)

Pacira BioSciences Reports Q2 Non-Gaap Earnings Per Share $0.41
Thursday, 8 Aug 2019 

Aug 8 (Reuters) - Pacira Biosciences Inc ::PACIRA BIOSCIENCES REPORTS SECOND QUARTER 2019 FINANCIAL RESULTS AND BUSINESS UPDATE.Q2 NON-GAAP EARNINGS PER SHARE $0.41.Q2 GAAP EARNINGS PER SHARE $0.06.Q2 REVENUE $102.6 MILLION VERSUS REFINITIV IBES ESTIMATE OF $100.5 MILLION.Q2 EARNINGS PER SHARE ESTIMATE $0.35 -- REFINITIV IBES DATA.UPDATED GUIDANCE FOR SELLING, GENERAL AND ADMINISTRATIVE (SG&A) EXPENSE AND REITERATED REMAINING GUIDANCE FOR 2019.SEES FY 2019 NON-GAAP SG&A EXPENSE IN RANGE OF $180 MILLION TO $190 MILLION.  Full Article

Pacira Biosciences Reports Q1 Loss Per Share $0.07
Thursday, 2 May 2019 

May 2 (Reuters) - Pacira Biosciences Inc ::PACIRA BIOSCIENCES REPORTS FIRST QUARTER 2019 REVENUES OF $91.3 MILLION.Q1 NON-GAAP EARNINGS PER SHARE $0.22.Q1 GAAP LOSS PER SHARE $0.07.Q1 REVENUE $91.3 MILLION VERSUS REFINITIV IBES ESTIMATE OF $92.2 MILLION.Q1 EARNINGS PER SHARE ESTIMATE $0.26 -- REFINITIV IBES DATA.SEES FY 2019 EXPAREL NET PRODUCT SALES OF $400 MILLION TO $410 MILLION.SEES FY 2019 IOVERA° NET PRODUCT SALES OF $8 MILLION TO $10 MILLION.  Full Article

Pacira Pharmaceuticals Reports Q4 Adj. EPS $0.47
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA REPORTS RECORD FOURTH QUARTER AND FULL YEAR REVENUES.Q4 NON-GAAP EARNINGS PER SHARE $0.47.Q4 GAAP EARNINGS PER SHARE $0.20.Q4 REVENUE $95.1 MILLION VERSUS REFINITIV IBES ESTIMATE OF $93.7 MILLION.Q4 EARNINGS PER SHARE ESTIMATE $0.28 -- REFINITIV IBES DATA.SAYS EXPAREL NET PRODUCT SALES EXPECTED TO BE IN RANGE OF $400M TO $410M IN 2019.SEES FY 2019 NON-GAAP GROSS MARGINS OF 75% TO 76%.  Full Article

Pacira Pharmaceuticals Says CMS & American Dental Association Establish New Reimbursement For Exparel
Friday, 2 Nov 2018 

Nov 2 (Reuters) - Pacira Pharmaceuticals Inc ::CENTERS FOR MEDICARE AND MEDICAID SERVICES AND AMERICAN DENTAL ASSOCIATION ESTABLISH NEW REIMBURSEMENT FOR EXPAREL.PACIRA PHARMACEUTICALS - CMS FINALIZED POLICY TO PROVIDE SEPARATE MEDICARE REIMBURSEMENT FOR EXPAREL WHEN ADMINISTERED IN AMBULATORY SURGICAL CENTERS.PACIRA PHARMACEUTICALS - AMERICAN DENTAL ASSOCIATION ESTABLISHED SEPARATE D-CODE TO REIMBURSE FOR EXPAREL INFILTRATION IN ORAL SURGERY PROCEDURES.PACIRA PHARMACEUTICALS - PRODUCT-SPECIFIC C-CODE FOR AMBULATORY SURGICAL CENTER PROCEDURES & D-CODE FOR DENTAL PROCEDURES TO TAKE EFFECT JAN. 1, 2019.  Full Article

Pacira Pharmaceuticals Reports Q3 GAAP Loss Per Share $0.02
Thursday, 1 Nov 2018 

Nov 1 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA PHARMACEUTICALS, INC. REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 NON-GAAP EARNINGS PER SHARE $0.31.Q3 GAAP LOSS PER SHARE $0.02.Q3 EARNINGS PER SHARE VIEW $0.08 -- THOMSON REUTERS I/B/E/S.SAYS FULL-YEAR EXPAREL NET PRODUCT SALES GUIDANCE INCREASED TO $325 TO $330 MILLION.QUARTERLY TOTAL REVENUES $83.45 MILLION VERSUS $67.34 MILLION.  Full Article

Aetna Inc Says Will Reimburse For Use Of Exparel In Ambulatory Surgical Centers In Florida And New Jersey
Tuesday, 30 Oct 2018 

Oct 30 (Reuters) - Pacira Pharmaceuticals Inc ::AETNA OFFERS EXPANDED COVERAGE FOR EXPAREL® IN SELECT AMBULATORY SURGICAL CENTERS.AETNA INC SAYS WILL REIMBURSE FOR USE OF EXPAREL IN AMBULATORY SURGICAL CENTERS IN FLORIDA AND NEW JERSEY AS PART OF A PILOT PROGRAM.AETNA - PURPOSE OF PILOT PROGRAM IS TO "INCENTIVIZE USE OF NON-OPIOID THERAPIES" FOR POSTSURGICAL PAIN MANAGEMENT IN AMBULATORY SURGICAL CENTERS.  Full Article

Aratana Therapeutics Says On July 5, Co, Pacira Pharmaceuticals Entered Amendment, Restatement Of Exclusive License, Development, Commercialization Deal
Tuesday, 10 Jul 2018 

July 9 (Reuters) - Pacira Pharmaceuticals Inc ::ARATANA THERAPEUTICS - ON JULY 5, CO, PACIRA PHARMACEUTICALS ENTERED AMENDMENT, RESTATEMENT OF EXCLUSIVE LICENSE, DEVELOPMENT, COMMERCIALIZATION DEAL.ARATANA THERAPEUTICS SAYS AMENDED AGREEMENTS PRIMARILY RELATE TO PROVIDING ACCESS AND SUPPLY OF A 10ML VIAL SIZE BY PACIRA TO CO FOR NOCITA(REG).  Full Article

Pacira Announces FDA Approval Of Supplemental New Drug Application For Exparel As A Nerve Block To Produce Regional Analgesia
Saturday, 7 Apr 2018 

April 6 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA ANNOUNCES FDA APPROVAL OF SUPPLEMENTAL NEW DRUG APPLICATION FOR EXPAREL® AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA.  Full Article

Pacira Pharmaceuticals Reports Q4 GAAP EPS Of $0.11
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE.Q4 NON-GAAP EARNINGS PER SHARE $0.38.Q4 GAAP EARNINGS PER SHARE $0.11.Q4 REVENUE ROSE 8 PERCENT TO $79.1 MILLION.SEES ‍ 2018 EXPAREL NET PRODUCT SALES OF $300 MILLION TO $310 MILLION​.SEES ‍ 2018 NON-GAAP GROSS MARGINS OF 70% TO 72%​.SEES ‍ 2018 NON-GAAP RESEARCH AND DEVELOPMENT EXPENSE OF $50 MILLION TO $60 MILLION​.Q4 EARNINGS PER SHARE VIEW $0.10, REVENUE VIEW $79.3 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Pacira Says FDA ‍committee ‍Did Not Reach A Unanimous Decision For Exparel As A Nerve Block To Produce Regional Analgesia​
Friday, 16 Feb 2018 

Feb 15 (Reuters) - Pacira Pharmaceuticals Inc ::PACIRA PHARMACEUTICALS STATEMENT ON FDA ADVISORY COMMITTEE FOR EXPAREL® FOR USE AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA.PACIRA PHARMACEUTICALS INC - ‍PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR COMPLETION OF REVIEW IS APRIL 6, 2018​.PACIRA PHARMACEUTICALS INC - ‍FOUR COMMITTEE MEMBERS VOTED TO RECOMMEND FDA APPROVAL OF EXPAREL SNDA​.PACIRA PHARMACEUTICALS INC -FDA ‍DID NOT REACH A UNANIMOUS DECISION ON EFFICACY AND SAFETY OF USE OF EXPAREL​.PACIRA PHARMACEUTICALS INC - ‍SIX COMMITTEE MEMBERS BELIEVED THAT MORE RESEARCH IS NEEDED TO FURTHER SUPPORT PROPOSED NEW INDICATION FOR EXPAREL SNDA​.PACIRA PHARMACEUTICALS INC -FDA ‍COMMITTEE'S FEEDBACK WILL BE CONSIDERED BY FDA IN ITS REVIEW OF COMPANY'S SNDA SEEKING EXPANSION OF EXPAREL LABEL​.PACIRA - FDA ‍COMMITTEE ‍DID NOT REACH A UNANIMOUS DECISION ON EFFICACY, SAFETY OF USE OF EXPAREL AS A NERVE BLOCK TO PRODUCE REGIONAL ANALGESIA​.  Full Article